← 返回

IL-21 工程化通过 CEBPD 增强 NK 细胞抗胶质母细胞瘤活性

英文原题:Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD.

查看英文原题

Interleukin-21 engineering enhances NK cell activity against glioblastoma via CEBPD.

PubMed 2024/08/12(内容时间) Cancer Cell Q1 · IF 56.1(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

胶质母细胞瘤(GBM)是一种侵袭性脑癌,治疗选择有限。自然杀伤(NK)细胞是具有强抗肿瘤活性的固有免疫细胞,可能为GBM提供一种有前景的治疗策略。我们比较了经工程化表达白细胞介素(IL)-15或IL-21的NK细胞的抗GBM活性。在多种体内模型中,IL-21 NK细胞在安全性和长期抗肿瘤活性方面均优于IL-15 NK细胞,而局部区域给药的IL-15 NK细胞被证明具有毒性且在控制肿瘤方面无效。IL-21 NK细胞显示出独特的染色质可及性特征,其中CCAAT/增强子结合蛋白(C/EBP),尤其是CEBPD,是调控其功能增强的关键转录因子。CEBPD缺失导致IL-21 NK细胞效力丧失,而其过表达则增强了NK细胞的长期细胞毒性和代谢适应性。这些结果表明,IL-21通过C/EBP转录因子驱动NK细胞的表观遗传重编程,增强其针对GBM的抗肿瘤疗效。

展开英文摘要原文

Glioblastoma (GBM) is an aggressive brain cancer with limited therapeutic options. Natural killer (NK) cells are innate immune cells with strong anti-tumor activity and may offer a promising treatment strategy for GBM.

We compared the anti-GBM activity of NK cells engineered to express interleukin (IL)-15 or IL-21. Using multiple in vivo models, IL-21 NK cells were superior to IL-15 NK cells both in terms of safety and long-term anti-tumor activity, with locoregionally administered IL-15 NK cells proving toxic and ineffective at tumor control.

IL-21 NK cells displayed a unique chromatin accessibility signature, with CCAAT/enhancer-binding proteins (C/EBP), especially CEBPD, serving as key transcription factors regulating their enhanced function. Deletion of CEBPD resulted in loss of IL-21 NK cell potency while its overexpression increased NK cell long-term cytotoxicity and metabolic fitness. These results suggest that IL-21, through C/EBP transcription factors, drives epigenetic reprogramming of NK cells, enhancing their anti-tumor efficacy against GBM.

论文信息

作者
Shanley M、Daher M、Dou J、Li S、Basar R、Rafei H、Dede M、Gumin J
第一作者单位
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA.United States
通讯作者单位
Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX 77030-4009, USA. Electronic address: krezvani@mdanderson.org.United States
期刊
Cancer cell2024 Aug 12
原文标识
PubMed 39137729 · DOI 10.1016/j.ccell.2024.07.007